Probiotic supplements are among the most commonly purchased products by people with inflammatory bowel disease (IBD), yet the evidence supporting their use remains complex and often misunderstood. Understanding what the research actually shows can help patients make informed decisions about whether probiotics deserve a place in their management plan.
What Are Probiotics?
Probiotics are live microorganisms, usually bacteria or yeasts, that confer a health benefit when consumed in adequate amounts. They are available as supplements in capsule, powder or sachet form, and are also found in fermented foods. The most commonly studied strains in IBD research belong to the Lactobacillus, Bifidobacterium and Saccharomyces groups, along with certain multi-strain formulations.
Not all probiotics are the same. Each strain has distinct properties, survival characteristics and potential effects on the gut. When evaluating probiotic research, the strain, dose, formulation and clinical context all matter.
The Evidence in Ulcerative Colitis
Probiotics have been studied more extensively in ulcerative colitis (UC) than in Crohn’s disease, with results varying widely depending on the strain and clinical scenario.
Inducing Remission
The evidence for probiotics inducing remission in active ulcerative colitis is weak. Most trials have found no significant benefit when probiotics are added to standard medical treatment. While some small studies reported modest improvements, larger controlled trials have not consistently replicated these findings.
Maintaining Remission
The strongest evidence in ulcerative colitis is for maintaining remission, particularly with a multi-strain formulation known as VSL#3, which contains eight bacterial strains. Several randomised controlled trials have shown that this specific product may be as effective as mesalazine in preventing relapse in people with UC who are already in remission. However, this finding applies to that particular formulation and cannot be generalised to other probiotic products.
Pouchitis
Pouchitis is inflammation of the ileal pouch, a surgically created reservoir formed after removal of the colon in some people with ulcerative colitis. VSL#3 has demonstrated clear efficacy in both preventing pouchitis onset after surgery and maintaining remission in chronic pouchitis. This represents one of the most robust areas of evidence for probiotic use in IBD-related conditions.
The Evidence in Crohn’s Disease
The evidence for probiotics in Crohn’s disease is notably weaker. Multiple trials have tested various strains and formulations, including Lactobacillus species, Saccharomyces boulardii and combination products, with largely disappointing results.
Probiotics have not been shown to induce remission in active Crohn’s disease, nor have they demonstrated reliable efficacy in maintaining remission after medical or surgical treatment. Some small studies suggested potential benefit in preventing post-operative recurrence, but larger trials have failed to confirm this.
The reasons for this difference between Crohn’s disease and ulcerative colitis are not fully understood but may relate to the transmural inflammation characteristic of Crohn’s, the involvement of different immune pathways or the variable location of disease throughout the gastrointestinal tract.
Why Probiotics Might Work (When They Do)
When probiotics do show benefit, several mechanisms are thought to be involved.
Competitive Exclusion
Certain probiotic strains may compete with harmful bacteria for nutrients and attachment sites on the gut lining, reducing the opportunity for pathogenic species to colonise and trigger inflammation. This is most relevant when gut bacteria balance has been disrupted, for example after antibiotic use or during active disease.
Immune Modulation
Some strains can influence immune cell activity in the gut lining, potentially promoting anti-inflammatory signalling molecules and reducing pro-inflammatory responses. This effect is strain-specific and occurs through interactions with immune receptors on the gut surface and in underlying tissue.
Barrier Function
Certain probiotics may support gut lining integrity by influencing mucus production and maintaining tight junctions, the connections between gut cells that regulate permeability. A more stable barrier can reduce bacterial translocation into underlying tissue, which may lower inflammatory signalling.
What the Research Does Not Show
It is equally important to understand the evidence limitations. Probiotics have not been shown to replace conventional medical treatment for IBD. They do not reduce the need for immunosuppressive or biologic medications in active disease and should not substitute evidence-based therapies.
There is also no strong evidence that probiotics can prevent IBD onset in at-risk individuals or significantly alter the long-term disease course. Most trials have focused on symptomatic improvement or relapse prevention rather than objective inflammation markers such as endoscopic healing or biomarker reduction.
Safety is another consideration. While probiotics are generally well tolerated, rare infections have been reported, particularly in severely immunosuppressed people or those with central venous catheters. The quality and viability of over-the-counter probiotic products can vary significantly, with some failing to contain the strains or doses stated on labels.
Practical Takeaways
- Probiotics are not a replacement for medical treatment in IBD and should not be used instead of prescribed therapies.
- In ulcerative colitis, specific multi-strain formulations may help maintain remission in some people and have strong evidence for preventing pouchitis.
- In Crohn’s disease, the evidence does not currently support routine probiotic use.
- Strain, dose and formulation matter. Results from one product cannot be assumed to apply to another.
- Discuss probiotic use with your gastroenterologist or dietitian, particularly if you are on immunosuppressive therapy.
- Focus on consistent, evidence-based approaches to managing inflammation rather than expecting probiotics to deliver significant changes on their own.
Conclusion
Probiotics occupy a nuanced space in IBD management. While certain strains and formulations have demonstrated benefit in specific situations, particularly in ulcerative colitis and pouchitis, the evidence does not support their routine use across all forms of IBD. The most important step is to ensure that any probiotic use is discussed with your healthcare team, forms part of a broader treatment plan and is based on realistic expectations informed by current evidence. Stability in IBD comes from consistent medical management, not from supplements alone.
References
- Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21-35. doi:10.1097/01.MIB.0000437495.30052.be
- Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(4):389-400. doi:10.1111/apt.14203
- Gionchetti P, Rizzello F, Helvig A, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202-1209. doi:10.1016/s0016-5085(03)00171-9
- Singh S, Stroud AM, Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015;(11):CD001176. doi:10.1002/14651858.CD001176.pub3
- Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2006;(4):CD004826. doi:10.1002/14651858.CD004826.pub2
- Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;(3):CD006634. doi:10.1002/14651858.CD006634.pub2
- Shadnoush M, Hosseini RS, Khalilnezhad A, et al. Effects of probiotics on gut microbiota in patients with inflammatory bowel disease: a double-blind, placebo-controlled clinical trial. Korean J Gastroenterol. 2015;65(4):215-221. doi:10.4166/kjg.2015.65.4.215
- Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004;10(11):PI126-131.
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.